Reunion Neuroscience Appoints Robert Alexander as Chief Medical Officer streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Oral Orexin Agonist Gets Breakthrough Therapy Status for Narcolepsy Type 1 neurologyadvisor.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from neurologyadvisor.com Daily Mail and Mail on Sunday newspapers.
Redirecting to U.S. Food and Drug Administration Grants Breakthrough Therapy Designation to Takeda's Investigational Compound, TAK-994, an Oral Orexin Agonist in Clinical Development for Narcolepsy Type 1 (NT1) q8dailynews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from q8dailynews.com Daily Mail and Mail on Sunday newspapers.
Global Roundup: Takeda and PeptiDream Expand CNS Collaboration biospace.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biospace.com Daily Mail and Mail on Sunday newspapers.
March 5, 2021 healthcare
Takeda Secures Global Rights from Ovid Therapeutics to Develop and Commercialize Soticlestat for the Treatment of Children and Adults with Dravet Syndrome and Lennox-Gastaut Syndrome
− Ovid eligible to receive up to $856M in payments, including a $196M upfront payment, regulatory and commercial milestone payments and tiered double-digit royalties on product sales
− Potential first-in-class therapy reduced seizure frequency in children with Dravet syndrome and Lennox-Gastaut syndrome in Phase 2 ELEKTRA study
− Original 2017 collaboration between Ovid and Takeda to conclude; Ovid will have no further development or milestone obligations
− Takeda plans to initiate Phase 3 studies in children and adults with Dravet syndrome and Lennox-Gastaut syndrome in calendar year Q2 2021